IBIO
iBio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.31
+0.77%Aug 28, 2026, 11:00 UTC
iBio, Inc. reported its financial results for the fiscal year ended June 30, 2026, and provided a corporate update on its progress, including the initiation of the Phase 1 clinical trial of IBIO-600.
Source:Aug 4, 2026, 11:00 UTC
iBio, Inc. appointed endocrinologist Molly Carr, M.D., as Chief Medical Officer on August 4, 2026, to lead its global clinical strategy, medical affairs, and regulatory initiatives.
Source:Jun 2, 2026, 11:00 UTC
iBio dosed the first participant in a Phase 1 clinical trial of IBIO-600 for obesity, becoming a clinical-stage company.
Source: